文献速递血液净化与透析慢性肾脏病

静脉硫代硫酸钠治疗血液透析患者血管钙化:系统综述与Meta分析

Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-a systematic review and meta-analysis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

该系统综述与Meta分析纳入6项研究共305例维持性血液透析患者,评估静脉硫代硫酸钠对血管钙化的疗效与安全性。结果显示硫代硫酸钠组冠状动脉和髂动脉Agatston评分进展及脉搏波速度增加均低于对照组,但可出现胃肠道症状与阴离子间隙酸中毒增加,未观察到骨密度下降。作者认为可能减轻血管钙化进展和动脉僵硬,需大型随机对照试验验证。

要点

  • 静脉硫代硫酸钠可能减缓血液透析患者冠状动脉和髂动脉钙化评分进展。
  • 硫代硫酸钠组脉搏波速度增加低于对照组,提示可能改善动脉僵硬。
  • 安全性方面可见胃肠道症状和阴离子间隙酸中毒增加,未观察到骨密度下降。

核心结论

  • 静脉硫代硫酸钠可能减轻血液透析患者血管钙化进展和动脉僵硬。
  • 需要大型且设计良好的随机对照试验进一步验证。

研究设计与样本

  • 系统综述与Meta分析,检索电子数据库中的临床试验数据,比较接受与未接受硫代硫酸钠治疗的患者结局。
  • 遵循PRISMA指南,采用随机效应模型,并进行Meta回归和敏感性分析,使用Cochrane工具评估偏倚风险。
  • 共纳入6项研究、305例参与者,平均年龄56岁,男性占56.6%,所有参与者均接受维持性血液透析。

主要发现

  • 冠状动脉Agatston评分进展(107例患者)的均数差为-241.27(95%CI:-421.50至-61.03),硫代硫酸钠组低于对照组。
  • 髂动脉Agatston评分进展(55例患者)的均数差为-382.00(95%CI:-751.07至-12.93),硫代硫酸钠组低于对照组。
  • 脉搏波速度增加(104例患者)的均数差为-1.29 m/s(95%CI:-2.24至-0.34 m/s),硫代硫酸钠组低于对照组。
  • 钙化评分变化与硫代硫酸钠方案之间未发现关联。
  • 安全性方面注意到胃肠道症状(如恶心)和阴离子间隙酸中毒增加,未观察到硫代硫酸钠降低骨密度。

局限性

  • 需要大型且设计良好的随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vascular calcification (VC) is a common comorbidity among patients with chronic kidney disease (CKD), indicating major cardiovascular events. This study aimed to evaluate the effects and safety of intravenous sodium thiosulphate (STS) for VC in CKD patients. METHODS: Electronic databases were searched for clinical trials that provided data comparing outcomes among patients treated with and without STS. The PRISMA guidelines were followed. Efficacy was assessed using calcification scores and arterial stiffness. Safety was examined by analyzing adverse symptoms, electrolytes and bone mineral density (BMD). Random-effects models were performed. Meta-regression and sensitivity analysis were done. The risk of bias was assessed using the Cochrane tools. RESULTS: Among the 5601 publications, 6 studies involving 305 participants (mean age: 56 years, male: 56.6%) with all participants on maintenance hemodialysis met eligibility criteria. For efficacy, the progression in Agatston scores in the coronary arteries [107 patients, mean difference (MD): -241.27, 95% confidence interval (95% CI): -421.50 to -61.03] and iliac arteries (55 patients, MD: -382.00, 95% CI: -751.07 to -12.93) was lower in the STS treated group compared with controls. The increase in pulse wave velocity was lower in the STS group (104 patients, MD: -1.29 m/s, 95% CI: -2.24 to -0.34 m/s). No association was found between the change in calcification scores and STS regimen. For safety, gastrointestinal symptoms (e.g. nausea) and increased anion gap acidosis were noted. No reduction in BMD by STS was observed. CONCLUSIONS: Intravenous STS may attenuate the progression of VC and arterial stiffness in hemodialysis patients. Large and well-designed randomized controlled trials are warranted.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wen W, Portales-Castillo I, Seethapathy R, et al. Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-a systematic review and meta-analysis. Nephrol Dial Transplant. 2023. PMID: 35521751. doi:10.1093/ndt/gfac171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。